FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385979663> ?p ?o ?g. }

• W4385979663 endingPage "104941" @default.
• W4385979663 startingPage "104941" @default.
• W4385979663 abstract "Ocrelizumab is a humanized anti-CD20 antibody that has been approved for the treatment of patients with multiple sclerosis (MS). Real-world data in the Middle East is very limited.To describe the effectiveness and safety of ocrelizumab treatment in MS patients in a real clinical setting.This is an observational, registry-based study. MS patients who were treated with ocrelizumab and completed at least one-year follow-up post-treatment were included. Baseline clinical and radiological characteristics were collected before ocrelizumab initiation. The relapse rate, disability measures, magnetic resonance image (MRI) activity (new T2 lesions and/or GD+ enhancing T1 lesions), and adverse events (AE) at the last follow-up visits were assessed.Data from 447 patients were analyzed, of which 260 (58.2%) were females. The mean age and mean disease duration were 37.39 ± 11.61 and 9.38 ± 7.57 years respectively. Most of the cohort was of a relapsing form (74.3%; n = 332), whereas active secondary and primary progressive forms represented 15.4% (n = 69) and 10.3% (n = 46) respectively. In the relapsing cohort, Ocrelizumab was prescribed in 162 (48.8%) patients due to highly active disease, and in 99 (29.8%) patients due to disease breakthrough while on prior therapies. In the last follow-up visits, most of the relapsing cohort was relapse-free (95.8% vs. 27.4%; p <0.001), had no evidence of MRI activity (3.6% vs. 67.5%; p <0.001) while EDSS score was stable (1.80+1.22 vs. 1.87+1.16; p < 0.104) when compared to baseline. NEDA-3 was achieved in 302 (91%) of RRMS patients. Confirmed disability progression was 27.5% and 23.9% in SPMS and PPMS respectively. Adverse events were observed in 139 (31.1%); infusion reactions and infections represented the most.This study showed that ocrelizumab is an effective and safe treatment for MS patients in a real clinical setting similar to what was observed in clinical trials." @default.
• W4385979663 created "2023-08-19" @default.
• W4385979663 creator A5000026859 @default.
• W4385979663 creator A5025338838 @default.
• W4385979663 creator A5049456235 @default.
• W4385979663 creator A5065095387 @default.
• W4385979663 date "2023-11-01" @default.
• W4385979663 modified "2023-10-14" @default.
• W4385979663 title "Real world study of ocrelizumab in multiple sclerosis: Kuwait experience" @default.
• W4385979663 cites W1816536644 @default.
• W4385979663 cites W1966849321 @default.
• W4385979663 cites W1968558564 @default.
• W4385979663 cites W1974000699 @default.
• W4385979663 cites W2009177607 @default.
• W4385979663 cites W2042725832 @default.
• W4385979663 cites W2070227911 @default.
• W4385979663 cites W2112165124 @default.
• W4385979663 cites W2122545833 @default.
• W4385979663 cites W2123021165 @default.
• W4385979663 cites W2124413251 @default.
• W4385979663 cites W2137350492 @default.
• W4385979663 cites W2171925564 @default.
• W4385979663 cites W2300679492 @default.
• W4385979663 cites W2490444229 @default.
• W4385979663 cites W2549644306 @default.
• W4385979663 cites W2561881161 @default.
• W4385979663 cites W2565433170 @default.
• W4385979663 cites W2919746350 @default.
• W4385979663 cites W2980841233 @default.
• W4385979663 cites W3015781103 @default.
• W4385979663 cites W3035737392 @default.
• W4385979663 cites W3045030255 @default.
• W4385979663 cites W3113499451 @default.
• W4385979663 cites W3113553077 @default.
• W4385979663 cites W3166908868 @default.
• W4385979663 cites W3178151623 @default.
• W4385979663 cites W3202037050 @default.
• W4385979663 cites W4213445516 @default.
• W4385979663 cites W4224247387 @default.
• W4385979663 cites W4316506655 @default.
• W4385979663 doi "https://doi.org/10.1016/j.msard.2023.104941" @default.
• W4385979663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37633033" @default.
• W4385979663 hasPublicationYear "2023" @default.
• W4385979663 type Work @default.
• W4385979663 citedByCount "0" @default.
• W4385979663 crossrefType "journal-article" @default.
• W4385979663 hasAuthorship W4385979663A5000026859 @default.
• W4385979663 hasAuthorship W4385979663A5025338838 @default.
• W4385979663 hasAuthorship W4385979663A5049456235 @default.
• W4385979663 hasAuthorship W4385979663A5065095387 @default.
• W4385979663 hasConcept C126322002 @default.
• W4385979663 hasConcept C197934379 @default.
• W4385979663 hasConcept C203014093 @default.
• W4385979663 hasConcept C2778843634 @default.
• W4385979663 hasConcept C2779338263 @default.
• W4385979663 hasConcept C2780640218 @default.
• W4385979663 hasConcept C2780653079 @default.
• W4385979663 hasConcept C71924100 @default.
• W4385979663 hasConcept C72563966 @default.
• W4385979663 hasConceptScore W4385979663C126322002 @default.
• W4385979663 hasConceptScore W4385979663C197934379 @default.
• W4385979663 hasConceptScore W4385979663C203014093 @default.
• W4385979663 hasConceptScore W4385979663C2778843634 @default.
• W4385979663 hasConceptScore W4385979663C2779338263 @default.
• W4385979663 hasConceptScore W4385979663C2780640218 @default.
• W4385979663 hasConceptScore W4385979663C2780653079 @default.
• W4385979663 hasConceptScore W4385979663C71924100 @default.
• W4385979663 hasConceptScore W4385979663C72563966 @default.
• W4385979663 hasLocation W43859796631 @default.
• W4385979663 hasLocation W43859796632 @default.
• W4385979663 hasOpenAccess W4385979663 @default.
• W4385979663 hasPrimaryLocation W43859796631 @default.
• W4385979663 hasRelatedWork W1532617462 @default.
• W4385979663 hasRelatedWork W2584761734 @default.
• W4385979663 hasRelatedWork W2615654765 @default.
• W4385979663 hasRelatedWork W2889485921 @default.
• W4385979663 hasRelatedWork W2906439237 @default.
• W4385979663 hasRelatedWork W3030177861 @default.
• W4385979663 hasRelatedWork W3160974410 @default.
• W4385979663 hasRelatedWork W4212881285 @default.
• W4385979663 hasRelatedWork W4296691977 @default.
• W4385979663 hasRelatedWork W4377136868 @default.
• W4385979663 hasVolume "79" @default.
• W4385979663 isParatext "false" @default.
• W4385979663 isRetracted "false" @default.
• W4385979663 workType "article" @default.